Combined Fulvestrant and Anastrozole as Neo-Adjuvant Endocrine Therapy in Postmenopausal Women With Hormone Receptor Positive Invasive Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
At a glance
- Drugs Anastrozole (Primary) ; Fulvestrant (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 20 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Sep 2017.
- 05 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.